New Army data show about one in four active-duty men could screen below a common testosterone threshold, raising high-stakes questions for troop health and readiness based on how the Pentagon applies the results.
Story Highlights
- A JAMA report estimates 25.7% of active-duty Army men would screen below 300 ng/dL
- The estimate shifts to 14.7% using a stricter 264 ng/dL cutoff, showing threshold sensitivity
- Policy links matter: the Pentagon has moved toward age-based testosterone screening
- A single low morning reading is not a diagnosis and needs repeat testing plus symptoms
What the Army Study Found and Why It Matters
Researchers analyzing 479 active-duty men across five Army posts estimated that 25.7% would have a morning testosterone value below 300 nanograms per deciliter if the whole force were screened. That projects to about 100,000 soldiers. The estimate dropped to 14.7% when the team used 264 nanograms per deciliter as the cutoff. Younger men had lower rates than older men. These findings came from a Military Health and Nutrition Examination Study conducted from 2024 to 2026.
The report also broke rates out by age. About 19.5% of men under 30 fell below 300 nanograms per deciliter. About 32.8% of men 30 and older did. This gap tracks with known biology, since testosterone often declines with age. The study used a single morning blood draw per person. The authors warned that one low value does not confirm disease, and that lab method differences can sway results near a cutoff.
Screening Versus Diagnosis: The Clinical Guardrails
National medical groups draw a line between a low screen and a diagnosis. The American Urological Association says clinicians can use below 300 nanograms per deciliter as a support threshold. But they should confirm with two early-morning tests on different days and check for symptoms before diagnosing low testosterone. The Endocrine Society gives the same core advice: make a diagnosis only when symptoms match and repeat morning tests show clear, consistent lows.
That clinical bar is why the Army’s estimated screening prevalence and the much lower rate of recorded disease do not match. A separate analysis of 2.84 million active-duty men from 2017 to 2024 found 12,112 diagnosed cases, or about 0.43%. That figure reflects full clinical workups, not one-time screens. It shows how moving from a single lab value to a medical diagnosis trims the numbers to those with confirmed, symptomatic deficiency.
Policy Crosswinds: Readiness, Care Needs, and Costs
Defense leaders have explored age-based screening for service members 30 and older. Media reports tied the new Army estimate to that push. If broad screening proceeds, more men will need repeat tests, visits, and counseling. Some may need treatment if symptoms fit and low values persist. That care load could be large, given that even the stricter cutoff still flags many. Health experts also point to fertility and family-planning questions around therapy choices.
Following a Department of War memorandum requiring annual testosterone screening for active-duty and reserve military personnel aged ≥30 years, a substantial proportion of male active-duty US Army personnel had a single morning #Testosterone value below commonly used screening… pic.twitter.com/bXBvhPMY8v
— JAMA (@JAMA_current) October 15, 2026
For troops and families, the stakes are practical. Service members want clear rules, privacy, and fair fitness standards. Leaders want ready units. Taxpayers want programs that work. Those goals can align if the Pentagon separates screening from diagnosis, follows national guidelines, and measures real outcomes like fitness, injury risk, sleep, and deployment performance. Tying lab numbers to results people feel in daily life can focus care on those who benefit most.
How to Read the Headline Number Without Spin
Numbers have context. Twenty-five point seven percent uses a 300 nanograms per deciliter cutoff; 14.7% uses 264. Both describe screens, not confirmed disease. One reading can be low due to sleep loss, illness, or shift work. Repeat morning testing reduces false alarms. Clear steps can help: standardize lab methods, confirm with a second test, check symptoms, and track whether care improves readiness. That mix respects science and the mission.
Sources:
medicalxpress.com, washingtonpost.com, media.jamanetwork.com, bbc.com
